Publication | Open Access

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

FibrosisNovel Autotaxin InhibitorAllergyMedicinePulmonary FibrosisPlacebo-controlled TrialPharmacotherapyPhase 2APharmacologyPulmonary Disease